



Baron Mid Cap Growth Strategy

June 30, 2021

DEAR INVESTOR:

PERFORMANCE

U.S. equities moved higher during the quarter in response to various factors, including robust macroeconomic data, ongoing fiscal stimulus, strong corporate earnings, and continued reductions in COVID-19 infection rates. The outlook for inflation remained uncertain, and was an important factor influencing investors' shifting preferences for growth versus value stocks during the quarter. Real Estate, Information Technology ("IT"), Energy, and Communication Services led the market higher in the period, while the Utilities, Consumer Staples, Industrials, Materials, and Consumer Discretionary sectors underperformed.

Against this backdrop, Baron Mid Cap Growth Strategy increased 10.06%, while the Russell Midcap Growth Index (the "Index") increased 11.07%, and the S&P 500 Index gained 8.55%.

Table I.
Performance
Annualized for periods ended June 30, 2021 – Figures in USD

	Baron Mid Cap Growth Strategy (net) ¹	Baron Mid Cap Growth Strategy (gross) ¹	Russell Midcap Growth Index ¹	S&P 500 Index ¹
Three Months ²	10.06%	10.33%	11.07%	8.55%
Six Months ²	8.97%	9.49%	10.44%	15.25%
One Year	36.19%	37.50%	43.77%	40.79%
Three Years	22.06%	23.25%	22.39%	18.67%
Five Years	21.80%	23.00%	20.52%	17.65%
Ten Years	15.81%	16.96%	15.13%	14.84%
Fifteen Years	11.77%	12.90%	12.10%	10.73%
Since Inception ³ (June 30, 1998)	10.13%	11.23%	9.79%	7.98%

For Strategy reporting purposes, the Firm is defined as all accounts managed by Baron Capital Management, Inc. ("BCM") and BAMCO, Inc. ("BAMCO"), registered investment advisers wholly owned by Baron Capital Group, Inc. As of June 30, 2021, total Firm assets under management are approximately \$53.5 billion. The Strategy is a time-weighted, total return composite of all mid-cap accounts greater than \$1 million using our standard investment process. Since 2010, accounts in the Strategy are market-value weighted and are included on the first day of the month following one full month under management. Prior to 2010, accounts were included on the first day of the quarter after one full quarter. Gross performance figures do not reflect the deduction of investment advisory fees. Actual client returns will be reduced by the advisory fees and any other expenses incurred in the management of the investment advisory account. A full description of investment advisory fees is supplied in our Form ADV Part 2A. Valuations and returns are computed and stated in U.S. dollars. Performance figures reflect the reinvestment of dividends and other earnings. The Strategy is currently composed of one mutual fund managed by BAMCO and separately managed accounts managed by BCM. BAMCO and BCM claim compliance with the Global Investment Performance Standards (GIPS®). To receive a complete list and description of the Firm's Strategies or a GIPS-compliant presentation please contact us at 1-800-99BARON.

Performance data quoted represents past performance. Current performance may be lower or higher than the performance data quoted. Past performance is no guarantee of future results. Returns could be reduced, or losses incurred, due to currency fluctuations.

¹ The **Russell Midcap® Growth Index** is an unmanaged index that measures the performance of small to medium-sized companies that are classified as growth and the **S&P 500 Index** measures the performance of 500 widely held large-cap U.S. companies. Russell Investment Group is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell is a trademark of Russell Investment Group. The indexes and the Strategy include reinvestment of dividends, net of withholding taxes, which positively impact the performance results. The indexes are unmanaged. Index performance is not Strategy performance. Investors cannot invest directly in an index.

² Not annualized.

³ The Strategy has a different inception date than its underlying portfolio, which is 6/12/87.

Health Care and Materials investments and lack of exposure to the underperforming Consumer Staples sector added the most value. Favorable stock selection in Health Care was driven by **IDEXX Laboratories, Inc.**, the global leader in veterinary diagnostics, software, and water microbiology testing. IDEXX was the largest contributor as veterinary visits continued their recovery from pandemic lows, leading to double-digit growth in veterinary practice revenues. Weighing instruments provider **Mettler-Toledo International, Inc.**, pharmaceutical packaging manufacturer **West Pharmaceutical Services, Inc.**, and DNA sequencing platform **Illumina, Inc.** also performed well after reporting strong quarterly financial results and raising full-year guidance. Within Materials, lower exposure to this lagging sector and outperformance of cleaning and hygiene solutions provider **Diversey Holdings, Ltd.** lifted relative results. Diversey reported solid quarterly results in its first earnings release since becoming a publicly traded company, with upside coming from market share gains in the Institutional segment and strong pricing and cost management.

Underperformance of investments in Communication Services, Industrials, and Financials detracted the most from relative results. Weakness in Communication Services came from online travel company **TripAdvisor, Inc.** and real estate and rental marketplace **Zillow Group, Inc.**, which were among the top detractors on an absolute basis. TripAdvisor's shares were pressured by news that competitor Expedia will expand its current rewards program to compete more aggressively with the company's new TripAdvisor Plus subscription offering. Zillow's stock price declined after second quarter revenue guidance came in slightly below Street expectations. Investor concerns about the potential impact of rising interest rates on the housing market also weighed on the company's shares. Negative stock selection in Industrials was driven by data and analytics vendor **Verisk Analytics, Inc.**, whose shares fell after the company's quarterly financial results came in slightly below Street expectations. The company's core Insurance segment remained strong, but pandemic-related weakness impacted its Energy and Financial Services segments. Real estate information and marketing services

Baron Mid Cap Growth Strategy

company **CoStar Group, Inc.** and private rocket and spacecraft manufacturer **Space Exploration Technologies Corp.** also hampered performance in the sector. Within Financials, underperformance of electronic trading platform **MarketAxess Holdings Inc.** and specialty insurer **Arch Capital Group Ltd.** detracted the most from relative results.

Table II.

Top contributors to performance for the quarter ended June 30, 2021

	Year Acquired	Percent Impact
IDEXX Laboratories, Inc.	2006	1.81%
Gartner, Inc.	2007	1.60
Mettler-Toledo International, Inc.	2008	0.78
West Pharmaceutical Services, Inc.	2014	0.61
TransUnion	2017	0.51

Shares of veterinary diagnostics leader **IDEXX Laboratories, Inc.** gained after reporting outstanding quarterly results. Total corporate revenues grew 21%, recurring revenues in its core companion animal segment grew 23%, its margins increased more than 800 basis points, and its normalized EPS grew a whopping 80%. The company's business continued to benefit from an ongoing recovery in veterinary office visits, which drives growth in veterinarians' expenditures on diagnostic instruments and testing performed both in clinics and laboratories. We remain optimistic about IDEXX's ability to continue growing its revenues and profits at elevated rates.

Shares of **Gartner, Inc.**, a leading provider of syndicated research primarily on the IT sector, contributed to performance after reporting financial results significantly better than investor estimates. Growth in the company's research business reaccelerated, led by its Global Business Sales segment. We believe this segment will continue to benefit from a multi-year investment cycle. In addition, Gartner's Conference segment should eventually benefit from increased corporate travel, now that COVID-19 vaccinations are widespread. We expect improved revenue growth and renewed focus on cost control to drive overall margin expansion and enhanced free cash flow generation. The company's balance sheet is in excellent shape, and we expect an acceleration in share repurchases.

Mettler-Toledo International, Inc. is the world's largest provider of weighing instruments for use in laboratory, industrial, and food retailing applications. Its shares rose on outstanding financial results, highlighted by 18% local currency sales growth, 49% operating profit growth, and 64% EPS growth, as well as an increase in its full-year earnings guidance. We believe Mettler is an excellent business with meaningful competitive advantages run by skilled operators. We remain optimistic that the company can compound earnings at attractive double-digit rates for years to come.

West Pharmaceutical Services, Inc. is a leading provider of components and systems for the packaging and delivery of injectable drugs. Shares rose on outstanding first quarter results, highlighted by 31% organic revenue growth, driven in part by COVID-19-related sales (mostly stoppers and seals for vials of vaccines), but also by strong organic growth in its core packaging business. We continue to believe West can generate durable high single-digit organic revenue growth, while also expanding its margins by at least 100 basis points annually.

TransUnion is a consumer credit bureau that businesses rely on to make credit and marketing decisions. Its shares increased after the company

reported strong quarterly results and raised full-year guidance. After providing disappointing initial 2021 guidance during the prior quarter, these solid results and improved outlook increased investors' confidence that the company should rebound alongside an improving economy. We continue to own the stock because we expect TransUnion to continue gaining market share in its core market, while utilizing its expertise in data aggregation and analysis to further diversify into attractive information services vertical markets.

Table III.

Top detractors from performance for the quarter ended June 30, 2021

	Year Acquired	Percent Impact
Tripadvisor, Inc.	2021	-0.36%
Guardant Health, Inc.	2020	-0.18
Zillow Group, Inc.	2015	-0.17
MarketAxess Holdings Inc.	2016	-0.14
Bumble Inc.	2021	-0.11

Tripadvisor, Inc. is an online travel company, with nearly half a billion unique monthly visitors, whose core business is hotel metasearch, driven by its extensive library of hotel reviews. Its shares fell on worries that new COVID-19 variants would delay the recovery of travel demand. In addition, investors appeared concerned that the company's new Tripadvisor Plus subscription offering, which launched in June, would face competitive pressures. We do not believe traditional travel loyalty programs will be materially competitive with the upfront savings offered by Tripadvisor Plus. We also believe that Tripadvisor is well positioned to benefit from inevitable pent-up consumer demand for travel.

Guardant Health, Inc. offers liquid biopsy tests for advanced stage cancer and recurrence monitoring, and it is also developing a test for early cancer detection. Shares fell during the quarter as many high-growth companies sold off. We maintain conviction in our long-term investment thesis, as we believe Guardant is a unique testing company that has the potential to transform the massive market for cancer care.

Zillow Group, Inc. operates leading U.S. real estate sites, a mortgage marketplace, and the Zillow Offers home-buying business. Its shares were pressured by rising mortgage rates and concerns over their potential impact on the housing market. In addition, Zillow issued second quarter revenue guidance that was slightly below Street expectations. Despite any macroeconomic uncertainty, we continue to believe that Zillow has substantial upside in all its business segments.

MarketAxess Holdings Inc. operates the leading electronic platform for corporate bond trading. Shares fell because of a slowdown in bond trading activity, particularly against last year's pandemic-driven spike. Market conditions were unfavorable as a result of lower volatility and narrower credit spreads. MarketAxess continued to increase its market share, but its share gains are typically more modest during periods of low market volatility. We continue to believe that MarketAxess will be the prime beneficiary of an ongoing secular shift to electronic trading in the corporate bond market.

Bumble Inc. is an online dating platform geared toward women with more than 40 million users. Shares declined on its 2021 revenue outlook that, while it exceeded Street estimates, was likely not as high as investors may have expected. Some uncertainty around the timing of the recovery in in-person dating also pressured shares. We exited our position during the period.

PORTFOLIO STRUCTURE

At June 30, 2021, Baron Mid Cap Growth Strategy held 64 positions. The Strategy's 10 largest holdings represented 37.3% of assets, and the 20 largest represented 59.7% of assets. The Strategy's largest weighting was in the IT sector at 30.6% of assets. This sector includes software companies, IT consulting firms, internet services companies, and data processing firms. The Strategy held 26.4% of its assets in the Health Care sector, which includes investments in life sciences companies, and health care equipment, supplies, and technology companies. The Strategy held 13.8% of its assets in the Industrials sector, which includes investments in research and consulting companies, industrial conglomerates, and machinery companies. The Strategy also had significant weightings in Financials at 10.1% of assets and Consumer Discretionary at 7.0% of assets.

Table IV.
Top 10 holdings as of June 30, 2021¹

	Year Acquired	Market Cap When Acquired (billions)	Quarter End Market Cap (billions)	Quarter End Investment Value (millions)	Percent of Net Assets
IDEXX Laboratories, Inc.	2006	\$2.5	\$53.9	\$447.5	7.2%
Gartner, Inc.	2007	2.9	20.8	362.7	5.8
Mettler-Toledo International, Inc.	2008	2.4	32.2	268.9	4.3
ANSYS, Inc.	2009	2.3	30.2	200.2	3.2
Vail Resorts, Inc.	1997	0.2	12.7	191.0	3.1
Bio-Techne Corporation	2015	4.0	17.5	180.1	2.9
CoStar Group, Inc.	2016	5.0	32.7	178.5	2.9
Verisk Analytics, Inc.	2009	4.9	28.3	167.9	2.7
West Pharmaceutical Services, Inc.	2014	2.9	26.5	161.4	2.6
TransUnion	2017	7.1	21.0	161.3	2.6

RECENT ACTIVITY

During the past quarter, the Strategy added to three positions. The Strategy eliminated three positions and reduced its holdings in 17 others.

Table V.
Top net purchases for the quarter ended June 30, 2021

	Quarter End Market Cap (billions)	Amount Purchased (millions)
Avalara, Inc.	\$13.9	\$33.5
RingCentral, Inc.	26.4	13.0
Stitch Fix, Inc.	6.5	11.8

This quarter we meaningfully added to our position in **Avalara, Inc.**, a leading cloud-based provider of transactional tax automation software. Avalara operates in a large (roughly \$15 billion) and relatively untapped market. We believe that the company is well positioned to benefit from several underlying secular trends. Following a recent U.S. Supreme Court

ruling (Wayfair vs. South Dakota), we expect heightened regulatory scrutiny on whether companies are collecting the appropriate sales taxes in all jurisdictions in which they operate. The rise of e-commerce, which entails sales across state lines, adds further complexity to this challenge. These trends should encourage the use of software solutions, which are inherently more efficient than people-based alternatives, to manage transactional tax calculations, record keeping, and tax filings.

Avalara is the clear leader for this software among mid-market customers. Relative to its competition, we believe the company is distinguished by its deep partner integrations, strong brand reputation, deep content database, native cloud-based technology, and effective sales force. The company is operating at near break-even profitability today due to ongoing growth investments. However, we expect to see Avalara meaningfully increase its margins and generate substantial free cash flow over the long term.

We believe that Avalara is well positioned to grow its revenues by at least 25% to 30% for the next several years. We expect this growth to be driven by several factors, including adding more mid-market customers, moving its offerings up-market into enterprise-size customers, expanding internationally, deepening its content database, becoming a broader compliance platform, and making selective acquisitions. We believe that this strong level of compounding growth will drive solid returns for the stock over a multi-year period.

Table VI.
Top net sales for the quarter ended June 30, 2021

	Amount Sold (millions)
The Toro Company	\$25.2
IDEXX Laboratories, Inc.	24.4
First Republic Bank	19.2
Gartner, Inc.	18.7
Willis Towers Watson Public Limited Company	17.4

We reduced our stakes in successful longtime holdings **IDEXX Laboratories, Inc.** and **Gartner, Inc.** to raise capital to allocate elsewhere in the Strategy. After making a reasonable profit, we sold our stake in **The Toro Company** over concerns that its recent positive business trends might prove unsustainable. We took some profits in **First Republic Bank** as its shares benefited from the recent rise in interest rates. We reduced our stake in **Willis Towers Watson Public Limited Company** given the uncertainty surrounding its pending acquisition by Aon plc.

OUTLOOK

We continue to be a long-term investor in businesses that we believe will benefit from long-lived secular growth trends, with sustainable competitive advantages, led by best-in-class management. We remain sensitive to valuation levels, particularly given the ongoing strength in the equity markets and the high near-term valuations accorded to many fast-growing, but speculative, companies. We invest in stocks that we believe, based on our deep fundamental research, will double in value over a five-year period,

¹ Portfolio characteristics, sector exposures, top 10 holdings, top net purchases, and top net sales are based on a representative account. Such data may vary for each client in the Strategy due to asset size, market conditions, client guidelines, and diversity of portfolio holdings. The representative account is the account in the Strategy that we believe most closely reflects the current portfolio management style for the Strategy. Representative account data is supplemental information.

Baron Mid Cap Growth Strategy

and all new and existing holdings must meet that objective. Please note that there is no guarantee that this objective will be met.

We believe that we have created value for our investors throughout the Strategy's long history by understanding and analyzing businesses better than many others. We do not invest based on our insights into macroeconomic, political, or public health issues. Consistent with that approach, our view about the likely near-term level of inflation does not determine our investment decisions. Similarly, we do not have a firm view about whether "growth" or "value" stocks are likely to lead the market going forward.

We continue to adhere to our investment methodology, while trying hard to identify beneficiaries of accelerating changes in technology and consumer preferences, many of which appear to have been permanently impacted by the pandemic. We remain optimistic that this approach will generate strong performance for our portfolio, regardless of the economic climate.

Sincerely,



Andrew Peck
Portfolio Manager

The performance of accounts in the Strategy may be materially different at any given time. Differences that may affect investment performance include cash flows, inception dates, and historical prices. Positions may not be the same or may be traded at different times. In addition, accounts in the Strategy may be pursuing similar investment strategies, but may have different investment restrictions.

Risks: Specific risks associated with investing in smaller companies include that the securities may be thinly traded and more difficult to sell during market downturns. Even though the Strategy is diversified, it may establish significant positions where the Adviser has the greatest conviction. This could increase volatility of the Strategy's returns. The Strategy may not achieve its objectives. Portfolio holdings are subject to change. Current and future portfolio holdings are subject to risk.

The discussions of the companies herein are not intended as advice to any person regarding the advisability of investing in any particular security. The views expressed in this report reflect those of the respective portfolio managers only through the end of the period stated in this report. The portfolio manager's views are not intended as recommendations or investment advice to any person reading this report and are subject to change at any time based on market and other conditions and Baron has no obligation to update them.

Baron Capital Management UK limited is an appointed representative of Mirabella Advisers LLP, Authorised and Regulated by the Financial Conduct Authority, FCA FRN 606792.

Baron Capital Management Malta Limited is a tied agent of Mirabella Malta Advisers Limited which is licensed and regulated by the Malta Financial Services Authority.